Category: Pharmaceuticals
Global Pharmaceuticals
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Anti-Counterfeit Packaging
... CAGR of 9.2% over the analysis period 2024-2030. Mass Encoding Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$109.6 Billion by the end of the ... Read More
-
Sports Nutrition Supplements
... at a CAGR of 5.8% over the analysis period 2024-2030. Amino Acids / Derivatives, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$4.6 Billion by the ... Read More
-
Al in Biotechnology Market by Function (Drug Design & Optimisation, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events), & End User - Global Forecast to 2029
... to grow as a result of the increasing demand for personalized therapies and precision medicines, and the growing applications of AI in epidemiological models for predicting disease outbreaks. It helps public health officials to respond ... Read More
-
Dental Infection Control Products
... 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Dental Infection Control Consumables, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$1.3 Billion ... Read More
-
Automotive Rubber-Molded Components
... at a CAGR of 5.4% over the analysis period 2024-2030. Ethylene Propylene Diene Monomer (EPDM) Material, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$31.1 Billion ... Read More
-
Generic Drugs
... CAGR of 6.5% over the analysis period 2024-2030. Small-Molecule Generics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$538.8 Billion by the end of the analysis ... Read More
-
Medical Membranes
... CAGR of 7.7% over the analysis period 2024-2030. Ultrafiltration Technology, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Neuromodulation
... 9.2% over the analysis period 2024-2030. Spinal Cord Stimulation, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$5.4 Billion by the end of the analysis period. ... Read More
-
Heavy-Duty Pumps
... CAGR of 4.8% over the analysis period 2024-2030. Centrifugal Pumps, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.1 Billion by the end of the analysis ... Read More
-
Hepatitis B Vaccines
... at a CAGR of 4.4% over the analysis period 2024-2030. Combination Vaccines, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.6 Billion by the end of ... Read More
-
High Pressure Pumps
... at a CAGR of 3.5% over the analysis period 2024-2030. Dynamic Pumps, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Missiles
... 4.7% over the analysis period 2024-2030. Surface-to-Surface Missiles, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$63.6 Billion by the end of the analysis period. Growth ... Read More
-
Assisted Reproductive Technology
... at a CAGR of 4.9% over the analysis period 2024-2030. In-Vitro Fertilization (IVF), one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$22.0 Billion by the end ... Read More
-
Automotive Lighting
... CAGR of 6.0% over the analysis period 2024-2030. Halogen Lighting, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$28.2 Billion by the end of the analysis ... Read More
-
Automotive Paints
... CAGR of 2.6% over the analysis period 2024-2030. Clearcoat, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$1.9 Billion by the end of the analysis period. ... Read More
-
Ophthalmic Pharmaceutical Drugs
... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More
-
Infectious Disease Diagnostics
... at a CAGR of 5.5% over the analysis period 2024-2030. Diagnostic Assays & Reagents, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$25.8 Billion by the ... Read More
-
Intrathecal Pumps
... CAGR of 5.1% over the analysis period 2024-2030. Morphine, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$115.9 Million by the end of the analysis period. ... Read More
-
Nanosensors
... 58.6% over the analysis period 2024-2030. Healthcare End-Use, one of the segments analyzed in the report, is expected to record a 61.3% CAGR and reach US$14.1 Billion by the end of the analysis period. Growth ... Read More
-
Ocular Implants
... CAGR of 4.2% over the analysis period 2024-2030. Glaucoma Implants, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$6.5 Billion by the end of the analysis ... Read More
-
Orthopedic Surgical Robots
... at a CAGR of 40.2% over the analysis period 2024-2030. Knee Surgery End-Use, one of the segments analyzed in the report, is expected to record a 37.6% CAGR and reach US$6.6 Billion by the end ... Read More
-
Orthopedic Trauma Devices
... at a CAGR of 4.8% over the analysis period 2024-2030. Internal Fixator, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$11.8 Billion by the end of ... Read More
-
Beta Interferon
... CAGR of 3.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$968.9 Million While China is Forecast to Grow at 4.5% CAGR The Beta Interferon market in the U.S. is estimated at ... Read More
Research Assistance
